RxDoctor Payments Data

Ronald Smith, MD

Internal Medicine · Reno, NVNPI 1215927124

Payments from drug & device makers

$4,085in general payments, 2019–2025

Across 52 payments — averaging $78.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$464
  • AbbVie$413
  • Boehringer Ingelheim$367
  • Johnson & Johnson$239
  • Merz North America, Inc.$231
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$4,080100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,085 in reported general payments places this provider in the 85th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$142,845
Medicare patients
337
Services billed
1,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban74$67,228
JardianceEmpagliflozin57$65,934
FarxigaDapagliflozin Propanediol34$45,344
XareltoRivaroxaban33$33,366
OzempicSemaglutide24$28,988
MyrbetriqMirabegron27$19,168
Tresiba Flextouch U-200Insulin Degludec21$12,407
Breo ElliptaFluticasone/Vilanterol12$8,227
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,097
Spiriva RespimatTiotropium Bromide12$6,148
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$6,104
PremarinEstrogens, Conjugated21$5,318
Levothyroxine Sodium411$5,120
Rosuvastatin Calcium341$4,632
Losartan Potassium375$3,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$194$72,54595 claims
Boehringer IngelheimJardiance, Spiriva Respimat$367$72,08369 claims
AstraZenecaFarxiga$1,064$45,34434 claims
Johnson & JohnsonXarelto$239$33,36633 claims
Novo NordiskOzempic$118$28,98824 claims
GSKBreo Ellipta, Trelegy Ellipta$160$15,32524 claims
AbbVieSynthroid$413$2,93151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →